Abstract | OBJECTIVES: To evaluate the frequency of the urokinase-type plasminogen activator (uPA) gene amplification and the sensitivity of prostate cancer cells to uPA inhibition, as we previously found one hormone-refractory prostate tumour with high-level amplification of the uPA (alias PLAU) gene, and also showed that a uPA inhibitor, amiloride, can effectively reduce the invasion potential of the PC-3 prostate cancer cell line. MATERIALS AND METHODS: Sixty-three locally recurrent hormone-refractory tumours and 78 hormone-refractory metastases from 29 patients who died from prostate cancer were analysed for uPA gene-copy number using fluorescence in situ hybridization. The Matrigel invasion assay was used to study the influence of uPA inhibitors on the invasive potential of prostate cancer cell lines. RESULTS: Of the locally recurrent hormone-refractory tumours, 21% had an increased copy number of uPA, but no high-level amplifications were found; 31% of the metastases had increased copy number and one high-level amplification of the uPA. Matrigel invasion assays with two specific uPA inhibitors, B428 and p-aminobenzamidine, showed that invasion of a prostate cancer cell line containing uPA gene amplification was inhibited by these small-molecule uPA inhibitors, while invasion of prostate cell lines without uPA gene amplification were not. CONCLUSION: These results suggest that selective inhibition of the uPA pathway in individuals whose tumours contain uPA gene amplification may provide therapeutic benefit.
|
Authors | Merja A Helenius, Kimmo J Savinainen, G Steven Bova, Tapio Visakorpi |
Journal | BJU international
(BJU Int)
Vol. 97
Issue 2
Pg. 404-9
(Feb 2006)
ISSN: 1464-4096 [Print] England |
PMID | 16430655
(Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Blood Proteins
- urokinase inhibitor
- Amiloride
- Urokinase-Type Plasminogen Activator
|
Topics |
- Amiloride
(therapeutic use)
- Blood Proteins
(therapeutic use)
- Gene Amplification
(genetics)
- Humans
- In Situ Hybridization, Fluorescence
(methods)
- Male
- Neoplasm Recurrence, Local
(drug therapy, genetics)
- Neoplasms, Hormone-Dependent
(drug therapy, genetics)
- Prostatic Neoplasms
(drug therapy, genetics)
- Reverse Transcriptase Polymerase Chain Reaction
(methods)
- Sensitivity and Specificity
- Urokinase-Type Plasminogen Activator
(genetics)
|